ACAM-Cdiff / Sanofi - LARVOL DELTA

Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial. (PubMed, Lancet Infect Dis) - P3 | "In adults at risk for C difficile infection, a bivalent C difficile toxoid vaccine did not prevent C difficile infection. Since the C difficile vaccine candidate met the criteria for futility, the study was terminated and clinical development of this vaccine candidate was stopped."

Clinical • Journal • P3 data • Infectious Disease